Clinical Trials · NCT00642538
A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Mannkind Corporation
- Enrollment
- 20
- Start date
- Feb 2008
- Locations
- 1 site, Netherlands
- Primary endpoint
- AUC 0-240 min post-prandial serum glucose